NO943101D0 - 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist - Google Patents

2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist

Info

Publication number
NO943101D0
NO943101D0 NO943101A NO943101A NO943101D0 NO 943101 D0 NO943101 D0 NO 943101D0 NO 943101 A NO943101 A NO 943101A NO 943101 A NO943101 A NO 943101A NO 943101 D0 NO943101 D0 NO 943101D0
Authority
NO
Norway
Prior art keywords
methano
receptor antagonist
quinolizine derivative
quinolizine
derivative
Prior art date
Application number
NO943101A
Other languages
English (en)
Norwegian (no)
Other versions
NO943101L (no
Inventor
Maurice Ward Gittos
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NO943101L publication Critical patent/NO943101L/no
Publication of NO943101D0 publication Critical patent/NO943101D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO943101A 1992-02-24 1994-08-23 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist NO943101D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92400474 1992-02-24
PCT/US1993/000880 WO1993017019A1 (en) 1992-02-24 1993-02-03 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist

Publications (2)

Publication Number Publication Date
NO943101L NO943101L (no) 1994-08-23
NO943101D0 true NO943101D0 (no) 1994-08-23

Family

ID=8211614

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943101A NO943101D0 (no) 1992-02-24 1994-08-23 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist

Country Status (14)

Country Link
EP (1) EP0628043A1 (cs)
JP (1) JPH07504192A (cs)
KR (1) KR100287933B1 (cs)
AU (1) AU675060B2 (cs)
CA (1) CA2130563C (cs)
FI (1) FI105917B (cs)
HU (1) HU216831B (cs)
IL (1) IL104821A (cs)
MX (1) MX9300948A (cs)
NO (1) NO943101D0 (cs)
NZ (1) NZ249346A (cs)
TW (1) TW226374B (cs)
WO (1) WO1993017019A1 (cs)
ZA (1) ZA931146B (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048597A1 (en) 1999-02-18 2000-08-24 Novartis Ag Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes
CA2600350C (en) 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2080727T3 (es) * 1988-02-23 1996-02-16 Merrell Pharma Inc Uso de quinolizina y derivados de quinolizinona en la fabricacion de medicamentos.
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines

Also Published As

Publication number Publication date
HU216831B (hu) 1999-09-28
NO943101L (no) 1994-08-23
KR950700297A (ko) 1995-01-16
WO1993017019A1 (en) 1993-09-02
EP0628043A1 (en) 1994-12-14
NZ249346A (en) 1995-10-26
IL104821A (en) 1997-01-10
CA2130563C (en) 1997-11-11
FI943872A0 (fi) 1994-08-23
HUT68249A (en) 1995-06-28
KR100287933B1 (ko) 2001-05-02
HU9402436D0 (en) 1994-10-28
CA2130563A1 (en) 1993-09-02
FI943872L (fi) 1994-08-23
AU675060B2 (en) 1997-01-23
TW226374B (cs) 1994-07-11
IL104821A0 (en) 1993-06-10
FI105917B (fi) 2000-10-31
ZA931146B (en) 1993-09-14
JPH07504192A (ja) 1995-05-11
MX9300948A (es) 1993-08-01
AU3603493A (en) 1993-09-13

Similar Documents

Publication Publication Date Title
DK0808312T3 (da) Indolderivater som 5-HT-receptorantagonist
DK0804419T3 (da) Quinolinderivater som tachykinin NK 3-receptor-antagonister
NO943348L (no) Kondenserte indolderivater som 5HT4-reseptorantagonister
FI943247L (fi) Piperatsiinijohdannaisia 5-HT-reseptoriantagonisteina
DK0856001T3 (da) Pyrimidinderivater som 5-HT2C-receptor-antagonister
FI922222A7 (fi) Kopplingsanordning, som foermaor laosa spinalosteosyntesfaestanordningar
FI925615L (fi) Stabiliserade farmaceutiska kompositioner, som innehaoller en HMG-CoA-reduktas-inhibitorfoerening
FI922143A7 (fi) Muscarinreceptorantagonister.
FI961628A7 (fi) Indolijohdannaisia NMDA-antagonisteina
FI922235L (fi) Foerfarande foer framstaellning av 3-aminopyridazinderivat, som verkar paodet centrala nervsystemet
AU2314195A (en) Benzofuran derivatives as d4 receptor antagonists
DK0854867T3 (da) Tetrahydroquinoliner som NMDA-antagonister
DK0710230T3 (da) Som CCK- eller gastrinantagonister anvendelige 1,5-benzodiazepinderivater
FI920735A7 (fi) Vattenhaltiga polymerdispersioner som innehaoller organiska foereningar med karbonat- och karbonylgrupper, liksom daermed framstaellda maolnings-och ytbehandlingssystem
FI951798A0 (fi) Bentsofuraanijohdannaiset 5-HT1-kaltaisina reseptoriantagonisteina
NO985970D0 (no) Indolinderivater anvendelige som 5_HT-2C-reseptor-antagonister
EP0754191A4 (en) NOVEL RECEPTOR TYPE PHOSPHOTYROSIN PHOSPHATASE-KAPPA
FI914453A7 (fi) Foerfarande foer kompressering av en videobild, som kodats digitaliskt
FI943872A0 (fi) 2,6-metano-2H-kinditsiinijohdannainen 5-HT3-reseptoriantagonistina
NO985972L (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
FI922903A0 (fi) 4-acetoxipiperidin derivat, deras framstaellningsfoerfarande och anvaendning som antagonist foer muskarina m-3 receptorer.
NO974205D0 (no) Heterocyklisk-substituerte piperazinonderivater som tachykininreceptor-antagonister
NO983656D0 (no) Heterocyklyl-ergolinderivater som 5-HT1A reseptorligander
FI922346A7 (fi) Muscarinreceptorantagonister.
NO963775L (no) Indol-derivater som CCK-reseptorantagonister